Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 16/20 | 0.51 |
| ▸ | MMP1 | P03956 | 16/20 | 0.51 |
| ▸ | MMP3 | P08254 | 15/20 | 0.51 |
| ▸ | MMP13 | P45452 | 15/20 | 0.51 |
| ▸ | MMP7 | P09237 | 14/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377037 | 0.91 | MMP1 (0.51) | MMP9MMP1MMP3MMP13MMP7 | |
| SCHEMBL778963 | 0.90 | MMP1 (0.64) | MMP9MMP1MMP3MMP13MMP7 | |
| SCHEMBL779000 | 0.88 | MMP1 (0.49) | MMP9MMP1MMP3MMP13MMP7 | |
| SCHEMBL779127 | 0.86 | MMP1 (0.51) | MMP9MMP1MMP3MMP13MMP7 | |
| SCHEMBL918750 | 0.85 | MMP1 (0.50) | MMP9MMP1MMP3MMP13MMP7 | |
| SCHEMBL778857 | 0.85 | MMP1 (0.49) | MMP9MMP1MMP3MMP13MMP7 | |
| SCHEMBL328472 | 0.84 | MMP1 (0.54) | MMP9MMP1MMP3MMP13MMP7 | |
| SCHEMBL918708 | 0.84 | MMP1 (0.54) | MMP9MMP1MMP3MMP13MMP7 | |
| SCHEMBL919122 | 0.83 | MMP1 (0.53) | MMP9MMP1MMP3MMP13MMP7 | |
| SCHEMBL919124 | 0.83 | MMP1 (0.53) | MMP9MMP1MMP3MMP13MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989661-B2 | Human ADAM-10 inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989661-B2 | Human ADAM-10 inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100105953-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105953-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105953-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | MMP9 9/4885MMP1 26/4885MMP3 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.